ArticleNeurology. Genetics2026
Expanding the Clinical Spectrum of Arboleda-Tham Syndrome: Neuroimaging Findings and Hematologic Manifestations.
Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Arboleda-Tham syndrome (ARTHS) is a rare autosomal dominant neurodevelopmental disorder caused by pathogenic variants in the lysine acetyltransferase 6A ( Methods: We retrospectively reviewed data from 14 patients with molecularly confirmed Results: Fourteen patients were identified, 79% of whom were male, with ages ranging from 2 to 14 years at the time of their last visit. Thirteen patients (93%) harbored late-truncating variants. Global developmental delay was universal, with marked speech impairment; most patients remained minimally verbal beyond age 5. Craniofacial dysmorphisms were observed in 11 patients (79%) and CHDs in 6 of the 10 assessed (60%). Notably, 3 of 11 patients (27%) exhibited hematologic abnormalities, ranging from transient neonatal neutropenia to severe aplastic anemia requiring hematopoietic stem cell transplantation. Brain imaging revealed type 1 Chiari malformation and white matter hyperintensities in 2 of the 10 assessed (20%), suggesting a broader neuroanatomic involvement. Radioulnar synostosis was observed in 1 patient, suggesting a possible expansion of the skeletal phenotype in ARTHS. Discussion: Our study broadens the recognized clinical features of ARTHS by reporting diverse neuroimaging findings, skeletal anomalies including radioulnar synostosis, and hematologic manifestations such as transient neonatal neutropenia and severe aplastic anemia. These findings reinforce the need for multidisciplinary surveillance in ARTHS and suggest potential avenues for further investigation into the role of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.